The Biotech Growth Trust

Latest Insights

Investment Companies |
Update

20.03.24

The Biotech Growth Trust — Onwards and upwards for performance recovery

Investment Companies |
Review

04.10.23

The Biotech Growth Trust — Historic low sector valuations

Investment Companies |
Review

15.03.23

Biotech Growth Trust (The) — Keeping the faith in smaller-cap biotech stocks

Investment Companies |
Review

05.09.22

The Biotech Growth Trust — No style drift, sticking to long-term winning ways

Visit Website

Sector

Investment Companies

Equity Analyst

Mel Jenner

Director, Investment Trusts

Key Management

Andrew Joy

Chairman
Geoffrey Hsu

Fund manager
Richard Klemm

Fund manager

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	3.9	9.0	26.1
Relative	1.1	2.0	20.1
52 week high/low	1010.0p/718.0p

Overview

The Biotech Growth Trust’s (BIOG’s) two co-managers, Geoff Hsu and Josh Golomb, at global healthcare specialist OrbiMed, believe that now could be an opportune time to consider the biotech sector as it is recovering from the longest and largest absolute and relative drawdown since 2006. The sector was negatively affected by sharply rising interest rates rather than a deterioration in industry fundamentals; indeed, the managers continue to refer to a ‘golden era’ of innovation within the biotech sector. BIOG’s relative performance has been through a difficult period given its high weighting in emerging (smaller-cap) biotech stocks, which performed significantly worse than the shares of large-cap biotech businesses during the sector sell-off.